Clarient Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer
June 16th, 2009
Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, today announced the launch of a new gene mutation test that can help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC).